Trial Profile
A Phase III, 18-Month, Extension Study to Evaluate the Safety of Asoprisnil in Subjects With Uterine Leiomyomata
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2007
Price :
$35
*
At a glance
- Drugs Asoprisnil (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions
- Sponsors TAP Pharmaceutical Products
- 12 Oct 2007 New trial record.